Loading clinical trials...

RECRUITINGNA

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study

NCT05874674•Wonju Severance Christian Hospital

View on ClinicalTrials.gov

Summary

Comparison nafamostat and low molecular weight heparin among dialysis patients

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Exclusion Criteria

•cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Locations (1)

Yonsei Unviersity Wonju College of Medicin

Wŏnju, Kangwondo, South Korea

Key Dates

Start Date

December 1, 2023

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2026

Last Updated

July 30, 2024

Enrollment

100

ESTIMATED participants

Conditions

Dialysis; ComplicationsBleeding

Interventions

Nafamostat Mesylate

DRUG

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

NCT07032792

Cardiac DiseaseSurgery+1 more

View study

RECRUITINGNA

WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients

NCT07447791

Acute Kidney Injury (Nontraumatic)Dialysis; Complications

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Inclusion Criteria

Exclusion Criteria

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients

National Longitudinal Cohort of Hematological Diseases

Isolated Rectal Bleeding in Newborns : Allergic Proctocolitis or Neonatal Colitis Transient - COLON Study

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants